Answers are grounded in this paper and cite their sources.
PURPOSE: To report a case of an 86-year-old man with a full thickness macular hole (FTMH) secondary to polypoidal choroidal vasculopathy (PCV) treated with bevacizumab. METHODS: A retrospective case report is presented. RESULTS: An 86-year-old male presented with a five-month history of metamorphopsia and decreased vision in his right eye and was found to have active exudation secondary to PCV with a concurrent FTMH. After four treatments with intravitreal bevacizumab, the FTMH resolved without surgical intervention. CONCLUSIONS: The patient's FTMH resolved with solely pharmacologic treatment as a result of treating his PCV with intravitreal bevacizumab. MH formation secondary to PCV is a rare finding, but may be successfully treated with pharmacologic therapy without surgical intervention.
No takes yet. Share an insight, caveat, or question.
Lindeke-Myers et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: